[Interview] The promise of oral SMA therapy and the flexibility gap between Korea and Japan

Treatment access for spinal muscular atrophy (SMA) in Korea remains constrained by structural barriers even as disease-modifying therapies become more widely available.

SMA is a genetic neuromuscular disease in which a lack of survival motor neuron protein leads to progressive muscle weakness, respiratory decline, and life-threatening complications.

For infants with type 1 SMA, the absence of treatment can mean a life expectancy of less than two years. As global evidence increasingly confirms that early diagnosis and early treatment change the course of the disease, Korean families still face rigid reimbursement rules that limit how and when they can receive therapy.

…

KBR (https://www.koreabiomed.com))

More Details​